Alexander Burges - Concepedia

Author

Alexander Burges

Ludwig-Maximilians-Universität München ORCID

Also Known As

A Burges, A. BURGES, A. Burges, ALEXANDER BURGES, Alexander Burges, Burges, A, Burges, Alexander, Klaus Baumann, Paul Buderath, Stefan Buchholz

396

Publications

9.6K

Citations

H-Index

109

Concepts

All Affiliations

Ludwig-Maximilians-Universität München LMU Klinikum Kliniken Essen-Mitte Charité - Universitätsmedizin Berlin Technische Universität Dresden

About

Alexander Burges is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	47	3.1K
2	Health Sciences	6	6	208
3	Public Health	2	2	58
4	Natural Sciences	1	1	75
5	Allergy	1	1	58

Alexander Burges

110

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, New England Journal of Medicine	2019	1.9K
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms Philipp Harter, Jalid Sehouli, Domenica Lorusso, New England Journal of Medicine	2019	571
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial M. M. Heiss, P. Murawa, P. Koralewski, International Journal of Cancer Tumor BiologyMedicinePuncture-free SurvivalImmunologyPathology	2010	547
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial Philipp Harter, Andreas du Bois, Maik Hahmann, Annals of Surgical Oncology Gynecologic SurgerySurgical OncologyGynecological SurgeryMedicineDesktop Ovar Trial	2006	415
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial I. Ray-Coquard, Alexandra Léary, Sandro Pignata, Annals of Oncology	2023	299
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer Philipp Harter, Jalid Sehouli, Annette Hasenburg, International Journal of Gynecological Cancer	2011	288
Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study Alexander Burges, Pauline Wimberger, Carolin Kümper, Clinical Cancer Research	2007	253
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) Pauline Wimberger, Nils Lehmann, Rainer Kimmig, Gynecologic Oncology Prognostic FactorsPrognostic EvaluationAdvanced Ovarian CancerMedicinePrognosis	2007	186
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
The intravascular volume effect of Ringer's lactate is below 20%: a prospective study in humans Matthias Jacob, Daniel Chappell, Klaus Hofmann‐Kiefer, Critical Care	2012	144

Page 1